glp-1 masld The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis GLP-1 and Glucagon Receptor Dual

Last reviewed: May 14, 2026 Last updated: May 14, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations

GLP-1 receptor agonists and the risk of thyroid cancer

Several Phase 3 trials cover type 2 diabetes (TRANSCEND-T2D), obstructive sleep apnea, MASLD, chronic kidney disease in patients with type 2 diabetes, knee osteoarthritis (TRIUMPH-4), and cardiovascular outcomes

Both labels warn about acute kidney injury related to dehydration and recommend renal monitoring when adverse reactions could lead to significant fluid loss

Microdosing Retatrutide Explore split-dose protocols, benefits, risks, and pharmacokinetic modeling

The absolute reduction in LFC at week 52 was significantly greater for the tirzepatide 10 mg and 15 mg group versus the insulin degludec group